Alumis Inc.
Alumis Inc. (Nasdaq: ALMS) is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (envu), is an allosteric TYK2 inhibitor being studied for plaque psoriasis and systemic lupus erythematosus; the company also develops A-005, a… From the company’s description.
In fiscal 2025, Alumis Inc. reported revenue of $24.05M and a net loss of $243.32M. Operations used $369.52M in cash. Over the twelve months to Jun 30, 2026, revenue was $7.40M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alumis Inc. does
In the company’s own words
Alumis Inc. (Nasdaq: ALMS) is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (envu), is an allosteric TYK2 inhibitor being studied for plaque psoriasis and systemic lupus erythematosus; the company also develops A-005, a CNS-penetrant TYK2 inhibitor for potential neurological and other indications. Its pipeline includes lonigutamab, a subcutaneous monoclonal antibody targeting IGF-1R for thyroid eye disease, acquired through the 2025 merger with ACELYRIN. Alumis also pursues earlier-stage discovery programs, including work on IRF5, using a precision data analytics platform to inform target and drug development. The company has no approved products or established commercial organization and relies on third parties to manufacture clinical supplies. Its website is https://alumis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1847367
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alumis Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alumis Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alumis Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alumis Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alumis Inc.'s last four quarterly filings that the numbers alone won't show?”